Feature | RSNA 2017 | January 29, 2018

3 High-impact Clinical Trials At RSNA 2017

Trials looked at use of shared decision-making with patients, cardiac CT and opto-acoustic breast imaging 

An example of opto-acoustic breast imaging using the Seno system.

An example of opto-acoustic breast imaging using the Seno system.  

January 26, 2017 — There were three high-impact clinical trials presented at the 2017 Radiological Society of North America (RSNA) meeting that offered radiology practice-changing clinical research.

Shared Decision-making in DCIS

For “Decision Quality and Quality of Life After Treatment for DCIS: A Trial of the ECOG-ACRIN Cancer Research Group,” presented by Ruth C. Carlos, M.D., M.S., and Janie M. Lee, M.D., the researchers hypothesized that patient satisfaction with the decision process in cases of ductal carcinoma in situ (DCIS) influences quality of life following treatment. In the study, they assessed quality of treatment decision-making among women with DCIS who were considered candidates for wide local excision and evaluated the impact of decision quality on quality of life after treatment.

The results showed that objective measures of decision quality, such as knowledge score and decision process score, were high. Only knowledge score predicted post-treatment physical and mental well-being. Although there was no significant difference in knowledge score by surgery type, decision process scores were significantly higher, indicating more shared decision-making, for mastectomy compared to wide local excision.

CT Can Better Classify Cardiac Risk

“Core Laboratory Versus Local Site Interpretation of Coronary CT Angiography (CTA): Association with Cardiovascular Events in the PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain),” presented by Michael T. Lu, M.D., and Jonathan A. Leipsic, M.D., investigates the concordance and relative prognostic value of central core laboratory versus local site interpretation for significant coronary artery disease.

In the PROMISE trial, 193 North American sites interpreted coronary CTA as part of the clinical evaluation of stable chest pain. CTA was also interpreted retrospectively by a central core lab blinded to clinical data, site interpretation, and outcomes. Concordance between core lab and site interpretation for significant CAD (greater than 50 percent luminal stenosis) was assessed.

The findings revealed that core lab interpretation of coronary CTA classified significantly fewer patients as having significant CAD compared to site interpretation, without a loss of predictive power for cardiovascular events.

This study was simultaneously published online in the journal Radiology.

 

Opto-Acoustic Imaging Better Assesses Breast Masses

The third trial in the session, “A Pivotal Study of Opto-Acoustic Imaging to Diagnose Benign and Malignant Breast Masses: A New Evaluation Tool for Radiologists,” will be presented by Erin I. Neuschler, M.D., and Constance D. Lehman, M.D., Ph.D.

The trial compares the specificity of an investigational optoacoustics (OA/US) breast imaging device with that of gray-scale ultrasound in evaluating breast masses. OA/US functional imaging fuses the high contrast resolution of optical imaging with the good spatial resolution of ultrasound.

A prospective 16-site study was undertaken to compare the BI-RADS classifications of breast masses assigned by independent readers using ultrasound alone to those assigned using OA/US images.

The researchers found that OA/US had better specificity than ultrasound in assessing breast masses and had an excellent negative likelihood ratio. These results suggest that OA/US offers the potential to reduce false positive diagnoses and to further enhance gray scale ultrasound accuracy in breast mass assessment.

This study was published online in the journal Radiology.

 

Read about other Key RSNA 2017 Study Presentations, Trends and Video.
 

Related Content

Sponsored Content | Videos | Pediatric Imaging | February 22, 2018
FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM SonoSite Inc., are offering a full-suite pediatric solutions...
Sponsored Content | Videos | Flat Panel Displays | February 21, 2018
This 5 megapixel, high-brightness color monitor has the high-definition display necessary for breast imaging.
Barco Highlights Imaging Workflow Compliance at HIMSS18
News | Flat Panel Displays | February 21, 2018
Barco will showcase its full line of radiology and mammography display systems with online quality assurance (QA)...
DenseBreast-info.org Launches European-Focused Education Coalition
News | Breast Density | February 19, 2018
DenseBreast-info.org (DB-I) announced plans for international expansion with specialized content for Europe and...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Sponsored Content | Videos | Imaging | February 15, 2018
David Widmann, president and CEO of Konica Minolta, looks at what the future of healthcare can bring to its customers,...
Sponsored Content | Videos | Artificial Intelligence | February 15, 2018
ITN Contributing Editor Greg Freiherr offers an overview of artificial intelligence advances at the Radiological Soci
Videos | Enterprise Imaging | February 13, 2018
ITN Contributing Editor Greg Freiherr offers an overview of enterprise imaging advances at the Radiological Society of...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
Overlay Init